4 completed, 3 active not recruiting, 1 terminated. 5 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Completed 1 |
Follow Guselkumab Dose 2: new trials by email Literature Review of Guselkumab Dose 2 trials Research Report on Guselkumab Dose 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 418 | 2022-09-13 | 2026-09-28 |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Crohn Disease | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 350 | 2022-01-19 | 2026-09-25 |
| A Study of Guselkumab in Participants With Systemic Sclerosis Guselkumab Dose 1, Guselkumab Dose 2, Placebo - Scleroderma, Systemic | Phase 2 | Completed | Janssen Pharmaceutical K.K. | 56 | 2021-02-24 | 2025-07-23 |
| A Study of Guselkumab in Participants With Active Lupus Nephritis Guselkumab Dose 1, Placebo, Guselkumab Dose 2 - Lupus Nephritis | Phase 2 | Terminated | Janssen Research & Development, LLC | 33 | 2020-09-15 | 2025-03-30 |
| A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1 - Colitis, Ulcerative | Phase 2 | Completed | Janssen Research & Development, LLC | 214 | 2018-11-20 | 2023-12-12 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3 - Hidradenitis Suppurativa | Phase 2 | Completed | Janssen Research & Development, LLC | 184 | 2018-09-04 | 2025-02-04 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 24 | 2018-05-31 | 2019-01-23 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Crohn's Disease | Phase 2 / Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 1409 | 2018-04-13 | 2026-09-28 |
Colitis, Ulcerative (2) · Crohn Disease (2) · Hidradenitis Suppurativa (1) · Lupus Nephritis (1) · Scleroderma, Systemic (1)
Janssen Research & Development, LLC (6) · Janssen Pharmaceutical K.K. (2)
United States (6) · Germany (5) · Japan (5) · Poland (5) · Australia (4) · Brazil (4) · Canada (4) · France (4) · Spain (4) · Taiwan (4) · Argentina (3) · Belgium (3) · China (3) · Czechia (3) · Hungary (3)
PMID 35134323, PMID 36738762, PMID 37317022, PMID 37528520, PMID 38104569, PMID 38488354, PMID 39673415, PMID 40113101, PMID 40357993, PMID 40684778, PMID 41544637, PMID 42065683
2018 (3), 2023 (3), 2017 (1)